Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment.
about
Animal models of myasthenia gravis: utility and limitationsSpecific immunotherapy of experimental myasthenia gravis by a novel mechanism.Vaccines against myasthenia gravis.Prophylactic effect of probiotics on the development of experimental autoimmune myasthenia gravis.T lymphocytes in food allergy: overview of an intricate network of circulating and organ-resident cells.Prospects for a T-cell receptor vaccination against myasthenia gravis.Myasthenia gravis and the tops and bottoms of AChRs: antigenic structure of the MIR and specific immunosuppression of EAMG using AChR cytoplasmic domains.Development of novel therapies for MG: Studies in animal models.Current and emerging treatments for the management of myasthenia gravis.Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades?Treatment strategies for myasthenia gravis: an update.Induction of oral tolerance to the acetylcholine receptor for treatment of myasthenia gravis.A Sensitive Method for Detecting Peptide-specific CD4+ T Cell Responses in Peripheral Blood from Patients with Myasthenia Gravis.A Th2 immune shift to heat shock protein 65 fails to arrest atherosclerosis: Proatherogenic role of Th2-deviated autoantibodies.Antigen-specific therapy of rheumatoid arthritis
P2860
Q26750632-73AE6939-8981-4C1B-AE55-AB127B58C97DQ33831279-192D4228-9E01-43E7-8701-DB5C6794B97DQ34433908-76860447-7447-4E56-86FF-4E22EEFEBB69Q34533028-4E5E1EA1-4F91-4F3F-8EC9-489174B2BBA3Q34764721-C1F7CA48-481B-42FE-B043-0077FACBA10BQ36238694-E5F1D9F8-DAD8-43EB-B891-666B333B992DQ37395079-805EE687-B4F6-4078-854F-9C9A19A47A0BQ37713733-C1ADDDE6-3375-4147-B34F-A8C53DE488DCQ37918361-2CC9BAE1-A17F-4715-BCE7-97C2D3C0FCACQ37967185-512253F1-0DC5-47E1-AE0A-026F0443DC98Q38024858-700554E0-B498-4A8D-9D4C-DFA54D575543Q40857962-F13093CB-1348-4B29-A500-FCD2242DBCB0Q46908307-0A1ACD01-62FD-49BB-9CAB-816CAA5A3D18Q47873108-4ADA32D2-B7A4-4E50-A9F0-5005F6E5176DQ57674015-E684555D-EFBB-46C2-A0D4-F9B366FFB8C3
P2860
Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment.
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Suppression of ongoing experim ...... receptor recombinant fragment.
@ast
Suppression of ongoing experim ...... receptor recombinant fragment.
@en
type
label
Suppression of ongoing experim ...... receptor recombinant fragment.
@ast
Suppression of ongoing experim ...... receptor recombinant fragment.
@en
prefLabel
Suppression of ongoing experim ...... receptor recombinant fragment.
@ast
Suppression of ongoing experim ...... receptor recombinant fragment.
@en
P2093
P2860
P356
P1476
Suppression of ongoing experim ...... receptor recombinant fragment
@en
P2093
P2860
P304
P356
10.1172/JCI8121
P407
P50
P577
1999-12-01T00:00:00Z